ETFs: Drug Pricing Policy Shapes PPH Risks in 2026
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesThe VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Analysts say social security’s COLA could climb in 2027 as inflation holds steady and energy costs remain volatile du...
Figure Technology Solutions is acquiring Kiavi in a $717 million deal, expanding its first-lien lending and investor-...
A high-profile insider sale by AeroVironment's CEO has investors asking what it means for the stock. This guide break...
When a CEO sells shares, investors watch closely. This piece breaks down Exponent's move by Catherine Corrigan, expla...
Anthropic's new findings on Claude's misalignment collide with Elon Musk's public remarks, as investors weigh AI narr...
Bitcoin remains in focus as investors weigh new geopolitical flare-ups. Markets are pricing risk as bitcoin (and peac...
As the debate over earnings reporting evolves, good quarterly earnings behavior becomes a competitive edge. This guid...
As Zoom prepares for 2026, investors want to know how the company will grow revenue, expand margins, and win with AI....
A personal financial disclosure reveals Trump earned more than a billion dollars from crypto ventures last year, incl...
Bitget introduces US stock options and tokenized stocks, a move that fuels debate over ownership on crypto platforms....
Oil crosses the critical $100 threshold as geopolitical tensions mount, sending Dow futures lower and pushing househo...